Last reviewed · How we verify
Off-label drug use
What "off-label" means
A drug's FDA-approved label specifies: the disease/condition treated, the patient population (often by age + characteristics), the dose, and the route of administration. Any use outside these parameters is "off-label." Examples: (a) approved for adults, used in children; (b) approved for one cancer type, used in another; (c) approved at one dose, used at a different dose. Off-label use is common — ~20% of all prescriptions, ~50% in oncology.
Legal framework
In the US, the FDA regulates manufacturer claims, not physician prescribing. Once a drug is approved for any indication, physicians can prescribe it off-label as they see fit. However, manufacturers cannot promote off-label uses — doing so is illegal under the Food, Drug, and Cosmetic Act. Major off-label promotion enforcement actions: Pfizer ($2.3B settlement, 2009), GSK ($3B, 2012), Johnson & Johnson ($2.2B, 2013).
Why off-label use happens
Three main reasons: (1) Evidence accumulates faster than label updates — clinical guidelines often recommend off-label use based on Phase 2 or 3 data before sponsors complete formal label-expansion FDA filings; (2) Rare populations — Phase 3 trials often exclude paediatric or elderly populations, but the drug works there too; (3) Compassionate access — for diseases without approved treatments, off-label use of analogous drugs is often the only option.
Reimbursement implications
Off-label use is often NOT covered by insurance. Payers typically require either (a) FDA approval for the indication, or (b) inclusion in major guideline (NCCN, NICE), or (c) extensive published evidence (compendium listings). Off-label without coverage means patients pay out-of-pocket — material when drugs cost $10,000+/month.
Common oncology examples
Avastin in breast cancer (approved in colon, lung, kidney — withdrawn for breast 2011 but still off-label prescribed). Keytruda in many rare cancer subtypes before formal approval. Bortezomib (Velcade) in amyloidosis. Lenalidomide in multiple non-myeloma indications. Most chemotherapy combinations have at least one off-label component.
FAQ
Is off-label prescribing risky for doctors?
Not legally — it's allowed. But medically: off-label use without supporting evidence increases liability risk. Most malpractice cases involving off-label use focus on inadequate informed consent rather than the prescription itself.
Can pharmaceutical companies discuss off-label use at all?
In limited contexts: responding to unsolicited physician questions, scientific exchange at medical conferences, peer-reviewed publication. They cannot proactively promote off-label uses in sales calls or marketing materials.
How does the FDA know about off-label use?
It doesn't directly track prescriptions. But it monitors adverse events via FAERS, reviews medical literature, and audits manufacturer marketing materials for off-label promotion.
Will the FDA approve a drug based on off-label evidence?
No — formal approval requires sponsor-led, FDA-regulated clinical trials. Off-label use provides hypothesis-generating evidence but isn't accepted as primary efficacy data for new indications.